Immunome (NASDAQ:IMNM) Announces Earnings Results

Immunome (NASDAQ:IMNM - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.08), Zacks reports. Immunome had a negative return on equity of 77.37% and a negative net margin of 1,687.08%.Immunome Price Performance3 Small-Cap Stocks With Big Growth PotentialShares of IMNM stock traded down $0.26 on Friday, hitting $15.24. The company's stock had a trading volume of 1,665,412 shares, compared to its average volume of 1,235,020. The stock has a market capitalization of $1.33 billion, a price-to-earnings ratio of -5.17 and a beta of 1.96. Immunome has a fifty-two week low of $5.15 and a fifty-two week high of $17.87. The firm's fifty day moving average price is $12.83 and its 200-day moving average price is $10.50. Wall Street Analyst Weigh InIMNM has been the subject of several research reports. Wedbush restated an "outperform" rating and set a $21.00 price target on shares of Immunome in a report on Friday. The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday, September 22nd. They issued a "buy" rating and a $26.00 target price for the company. Guggenheim reissued a "buy" rating and set a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. Weiss Ratings restated a "sell (d-)" rating on shares of Immunome in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered Immunome from a "hold" rating to a "sell" rating in a report on Saturday. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $23.20.Get Our Latest Stock Analysis on IMNMInstitutional Trading of ImmunomeInstitutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its stake in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after acquiring an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares during the period. Creative Planning bought a new stake in Immunome during the second quarter worth approximately $167,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Immunome by 44.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 46,821 shares of the company's stock valued at $316,000 after purchasing an additional 14,398 shares during the last quarter. Finally, Rhumbline Advisers raised its position in shares of Immunome by 22.0% in the second quarter. Rhumbline Advisers now owns 108,414 shares of the company's stock valued at $1,008,000 after purchasing an additional 19,526 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock. Immunome Company Profile (Get Free Report)Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.Read MoreFive stocks we like better than ImmunomeBest of the list of Dividend Aristocrats: Build wealth with the aristocrat indexRivian’s Chart Says Go, But Some Analysts Still Say NoWhat is the Shanghai Stock Exchange Composite Index?e.l.f. Sell-Off Is a Good Time to Buy, According to AnalystsInsider Selling Explained: Can it Inform Your Investing Choices?T-Mobile Is The Most Oversold Mega-Cap Stock—Time to Buy?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Immunome Right Now?Before you consider Immunome, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.While Immunome currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here